<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03590223</url>
  </required_header>
  <id_info>
    <org_study_id>2017-02156 (ch17berdajs)</org_study_id>
    <nct_id>NCT03590223</nct_id>
  </id_info>
  <brief_title>Glycosylated Hemoglobin and Risk of Perioperative Major Cardiovascular Events in Diabetic Patients Undergoing Coronary Bypass Revascularization (HbA1c)</brief_title>
  <official_title>Glycosylated Hemoglobin and the Risk of Perioperative Major Cardiovascular Events in Diabetic Patients Undergoing Coronary Bypass Revascularization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glycosylated Hemoglobin (HbA1c) is considered as one of the best markers to assess the
      glycaemia treatment over a period of 3 to 4 months, and is considered as predictive marker
      for perioperative mortality and morbidity. The impact of the elevated HbA1c on the risk of
      perioperative major cardiovascular events in patients undergoing coronary bypass
      revascularization (by retrospective analysis of perioperative cardiovascular events and
      preoperative HbA1c) is evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 29, 2017</start_date>
  <completion_date type="Actual">August 21, 2018</completion_date>
  <primary_completion_date type="Actual">August 21, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>occurence of Major adverse cardiac events</measure>
    <time_frame>perioperative = in hospital</time_frame>
    <description>myocardial infarction, cardiac related death, stroke</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>occurence of severe renal insufficiency</measure>
    <time_frame>perioperative = in hospital</time_frame>
    <description>application of renal replacement therapy (renal dialysis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>occurence of sternal wound infection</measure>
    <time_frame>perioperative = in hospital</time_frame>
    <description>sternal wound infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>perioperative = in hospital</time_frame>
    <description>death rate perioperative</description>
  </secondary_outcome>
  <enrollment type="Actual">589</enrollment>
  <condition>Cardiovascular Event</condition>
  <condition>Coronary Artery Bypass Graft</condition>
  <condition>Diabetes Mellitus</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Coronary Bypass Revascularization</intervention_name>
    <description>analysis of perioperative major cardiovascular events in diabetic patients</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        all patients with diabetes mellitus

          -  undergoing coronary bypass revascularization at the Klinik für Herzchirurgie,
             Universitätsspital Basel, Spitalstrasse 21, CH 4031-Basel since 2012

          -  who did not disapprove of use of data for research purposes

          -  statistic stratification in serum level of glycosylated hemoglobin (HbA1c) &gt; 6.5% and
             &lt;/= 6.5%
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with Diabetes mellitus undergoing coronary bypass revascularization since
             2012

        Exclusion Criteria:

          -  disapproval of use of data for research purposes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denis Berdajs, PD Dr. med</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herzchirurgie University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>July 4, 2018</study_first_submitted>
  <study_first_submitted_qc>July 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2018</study_first_posted>
  <last_update_submitted>September 10, 2018</last_update_submitted>
  <last_update_submitted_qc>September 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

